Medical

Magazine articles on health care providers, pharmaceutical companies, and medical technology.

Old Articles: <Older 3731-3740 Newer>

The Motley Fool May 22, 2007 Mike Havrilla	Avandia Safety Concerns Weigh Down Glaxo Shares of GlaxoSmithKline dropped nearly 8%, after a study raised safety concerns about the company's widely used diabetes drug, Avandia.
The Motley Fool May 21, 2007 Brian Lawler	DUSA's Orphan Isn't Unique The pharmaceutical gets "orphan drug" status for its lead compound. Investors, take note.
The Motley Fool May 21, 2007 Mike Havrilla	Novel Developments at Neose Neose could have positive clinical trial results in the near future. For a micro-cap biotech stock, Neose has impressive institutional ownership, exceeding 50% of all shares.
Entrepreneur June 2007 Chris Penttila	Creative License? A portfolio licensing agreement between bio-tech companies MedImmune and Genentech was going well - that is, until it went bad.
Chemistry World May 18, 2007 Hepeng Jia	China's Battle with Fake Drugs While China's pharmaceutical industry is experiencing rapid growth, a boom in counterfeit drugs is costing human lives and eroding the public's confidence in medical products.
The Motley Fool May 18, 2007 Mike Havrilla	Innovative Inovio Given the company's strong partnerships and recently strengthened balance sheet, biotech investors should look into Inovio in advance of potentially positive clinical developments for the MedPulser later this year.
The Motley Fool May 18, 2007 Mike Havrilla	Ample Opportunities for Alnylam The biotech's RNAi pipeline and cutting-edge technology make it a prime takeover candidate. Investors, take note.
BusinessWeek May 28, 2007 Bruce Einhorn	The Rush To Test Drugs In China Despite ethical concerns, Big Pharma is recruiting more patients for clinical trials in China.
The Motley Fool May 17, 2007 Mike Havrilla	Picking Up the Pace at Cadence Two of this pharma's drugs in testing could find their niche serving hospital patients. Investors, take note.
The Motley Fool May 17, 2007 Mike Havrilla	Javelin Is Right on Target The company reformulates existing drugs to fill unmet needs, making its stock worthy of consideration.
<Older 3731-3740 Newer> Return to current articles.